VIDEO: Long term survivorship for CAR-T in myeloma undetermined

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

This is a great question, and I think in the domain of things like multiple myeloma and relapsed and refractory non-Hodgkin lymphomas, there is much to be determined. We know that with technologies like these, there is the possibility of producing patients who remain negative for minimal residual disease for a period of time. What does that mean over the long haul has yet to be determined. So how long can patients sustain these responses and remissions across the board with CAR T-cells? That's something that we seek to really understand at a deep level. There are some patients in the domain of lymphoma and acute leukemias where we're seeing very protracted remissions that we hope translate into long-term disease-free survival without additional therapy. I can't make that prediction for multiple myeloma but I would love to. That said, when we think about the practical, everyday management of people, there are issues that we want to care for patients related to CAR T-cells. In the short term, monitoring for cytokine release syndromes or neurological toxicities, in the longer term, looking for qualitative changes to their immunological status. That does require a certain sort of expert level of support that we wanna maintain around the patient. And part of the value of getting care at a center that has the kinds of expertise that the disease teams at City of Hope deliver is that that expertise, as the knowledge base evolves dramatically over the next couple of years, it's there in the hands of those caregivers and available to those patients for the continuity of their care. And I think that's an essential element. As we learn, you wanna get your care in a place where that knowledge very rapidly translates into the reality of what the patient's getting.